PANCREOX: A randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT).-Reference-Cited by-同舟云学术

PANCREOX: A randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT).

Published:2014-05-20 Issue:15_suppl Volume:32 Page:4022-4022
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Gill Sharlene¹,Ko Yoo-Joung²,Cripps M. Christine³,Beaudoin Annie⁴,Dhesy-Thind Sukhbinder K.⁵,Zulfiqar Muhammad⁶,Zalewski Pawel⁷,Do Thuan⁸,Cano Pablo Oscar⁹,Lam Wendy¹⁰,Dowden Scot D.¹¹,Grassin Helene¹²,Stewart John¹³,Moore Malcolm J.¹⁴

Affiliation:

1. British Columbia Cancer Agency, Vancouver, BC, Canada

2. Division of Medical Oncology and Hematology, Sunnybrook Health Sciences Centre, Odette Cancer Centre, Toronto, ON, Canada

3. The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada

4. Centre hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada

5. Juravinski Cancer Centre, Hamilton, ON, Canada

6. British Columbia Cancer Agency, Abbotsford, BC, Canada

7. Durham Regional Cancer Centre, Oshawa, ON, Canada

8. BC Cancer Agency - ACC, Abbotsford, BC, Canada

9. North Eastern Cancer Centre/Health Sciences North, Sudbury, ON, Canada

10. Burnaby Hospital Cancer Centre, Burnaby, BC, Canada

11. Tom Baker Cancer Centre, Calgary, AB, Canada